Hangcheng Fu1,2, Yu Zhu1,2, Yiwei Wang3, Zheng Liu1,2, Junyu Zhang1,2, Zewei Wang4, Huyang Xie1,2, Bo Dai1,2, Jiejie Xu5, Dingwei Ye6,7. 1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Department of Urology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. 5. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. jjxufdu@fudan.edu.cn. 6. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. dwyeli@163.com. 7. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. dwyeli@163.com.
Abstract
PURPOSE: The role played by the innate immune system in determining the clinical outcome of clear-cell renal cell carcinoma (ccRCC) was still blurred. This study was designed to investigate the prognostic significance of tumor infiltrating mast cells (TIMs) in ccRCC. METHODS: The study retrospectively enrolled a training set (474 patients) and a validation set (188 patients) with nonmetastasis (pT1-4N0M0) ccRCC from two institutional medical centers of China. TIMs was evaluated by immunohistochemical staining of tryptase and its association with clinicopathologic features and prognosis were evaluated. RESULTS: In ccRCC tissues, TIMs ranged from 0 to 103 cells/mm2 and 0 to 113 cells/mm2 in the training set and validation set, respectively. TIMs was negatively correlated with tumor size (P < 0.001 and P < 0.001, respectively), pathological T stage (P = 0.005 and P = 0.007, respectively) and Fuhrman grade (P < 0.001 and P < 0.001, respectively). Patients with abundant TIMs infiltration showed significantly longer cancer-specific survival in the training cohort and the validation cohort (P < 0.001 and P < 0.001). Patients with abundant mast cell infiltration showed significantly longer overall survival in the TCGA cohort (P < 0.001). Moreover, multivariate analysis identified TIMs as an independent prognostic factor for cancer-specific survival (CSS) and relapse-free survival (RFS). Also, TIMs was significantly correlated with CSS and RFS of the mediate and high-risk patients in the training cohort and the validation cohort. CONCLUSIONS: TIMs density is a powerful independent prognostic factor for CSS and RFS in patients with nonmetastasis (pT1-4N0M0) ccRCC.
PURPOSE: The role played by the innate immune system in determining the clinical outcome of clear-cell renal cell carcinoma (ccRCC) was still blurred. This study was designed to investigate the prognostic significance of tumor infiltrating mast cells (TIMs) in ccRCC. METHODS: The study retrospectively enrolled a training set (474 patients) and a validation set (188 patients) with nonmetastasis (pT1-4N0M0) ccRCC from two institutional medical centers of China. TIMs was evaluated by immunohistochemical staining of tryptase and its association with clinicopathologic features and prognosis were evaluated. RESULTS: In ccRCC tissues, TIMs ranged from 0 to 103 cells/mm2 and 0 to 113 cells/mm2 in the training set and validation set, respectively. TIMs was negatively correlated with tumor size (P < 0.001 and P < 0.001, respectively), pathological T stage (P = 0.005 and P = 0.007, respectively) and Fuhrman grade (P < 0.001 and P < 0.001, respectively). Patients with abundant TIMs infiltration showed significantly longer cancer-specific survival in the training cohort and the validation cohort (P < 0.001 and P < 0.001). Patients with abundant mast cell infiltration showed significantly longer overall survival in the TCGA cohort (P < 0.001). Moreover, multivariate analysis identified TIMs as an independent prognostic factor for cancer-specific survival (CSS) and relapse-free survival (RFS). Also, TIMs was significantly correlated with CSS and RFS of the mediate and high-risk patients in the training cohort and the validation cohort. CONCLUSIONS:TIMs density is a powerful independent prognostic factor for CSS and RFS in patients with nonmetastasis (pT1-4N0M0) ccRCC.
Authors: Rong Lu; Payal Kapur; Bijay S Jaiswal; Tao Wang; Raquibul Hannan; Ze Zhang; Ivan Pedrosa; Jason J Luke; He Zhang; Leonard D Goldstein; Qurratulain Yousuf; Yi-Feng Gu; Tiffani McKenzie; Allison Joyce; Min S Kim; Xinlei Wang; Danni Luo; Oreoluwa Onabolu; Christina Stevens; Zhiqun Xie; Mingyi Chen; Alexander Filatenkov; Jose Torrealba; Xin Luo; Wenbin Guo; Jingxuan He; Eric Stawiski; Zora Modrusan; Steffen Durinck; Somasekar Seshagiri; James Brugarolas Journal: Cancer Discov Date: 2018-06-08 Impact factor: 39.397
Authors: Thomas Denize; Subrina Farah; Alessia Cimadamore; Abdallah Flaifel; Emily Walton; Maura A Sticco-Ivins; Chris Labaki; David A Braun; Maxine Sun; Evelyn Wang; Wanling Xie; Toni K Choueiri; Sabina Signoretti Journal: Clin Cancer Res Date: 2022-02-15 Impact factor: 13.801